No Data
No Data
Analyst Estimates: Here's What Brokers Think Of Tango Therapeutics, Inc. (NASDAQ:TNGX) After Its First-Quarter Report
The analysts might have been a bit too bullish on Tango Therapeutics, Inc. (NASDAQ:TNGX), given that the company fell short of expectations when it released its first-quarter results last week. E
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Tango Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Tango Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Tango Therapeutics on Promising PRMT5 Inhibitors and Strong Financials
Tango Therapeutics (TNGX) Gets a Buy From Barclays
Tango Therapeutics' Cash Position Of $344M As Of March 31, 2024; Cash Runway Into Late 2026 Expected
Tango Therapeutics' Cash Position Of $344M As Of March 31, 2024; Cash Runway Into Late 2026 Expected